{"entity":{"id":"nct07241416","kind":"trial","name":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Rezvilutamide run by Jiangsu HengRui Medicine Co., Ltd. in prostate cancer, now recruiting.","summary":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer is a phase 3 interventional study registered as NCT07241416 by Jiangsu HengRui Medicine Co., Ltd., with 206 participants planned, started 2025-12-05. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer (mHSPC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07241416","url":"https://clinicaltrials.gov/study/NCT07241416"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mhspc"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":["rezvilutamide"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07241416","phase":"3","setting":"A Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Study of Rezvilutamide Combined With Androgen Deprivation Therapy (ADT) Versus Enzalutamide Combined With ADT for Treating Low-volume Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","participation":[{"nct":"NCT07241416","source":"https://clinicaltrials.gov/study/NCT07241416","fetchedAt":"2026-10-07T16:55:34.394Z","studySha256":"2b5e7668b55d79429eb9c6b0dc76b44e04e729ab7aabf629409648928d6af003","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-11","leadSponsor":"Jiangsu HengRui Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":206,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-12-05","startedType":"actual","enrolled":206,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07241416/","neighbours":{"cancer":[{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","route":"/drugs/rezvilutamide/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}